In the recent past, females have been hearing solely awful news regarding estrogen-progestin usage for easing symptomatic menopausal women.

During 2002, scientists put a stop to a key government-backed trial of the so-dubbed combination therapy, a segment of the WHI (Women’s Health Initiative), when females who took such hormones were found to be having an augmented risk for strokes, heart attacks & cancer of the breasts.

Alarmed females ditched hormones in hoards. However, currently a contentious novel reassessment of information indicates some positive news – particularly for a section of females taking solely estrogen minus the progestin for treating menopausal symptoms might in fact, be shielded from developing breast cancer.

The reassessment that was made public in the lately held annual San Antonio Breast Cancer convention, attracted instant censure from scientists that stated it was simply a rehashing of older information. However, Doctor J. Ragaz who put forth this report stated that the proof about estrogen providing breast cancer protection has been mostly overlooked, & that its high-time for directing attention on the discovery.

Prof. Ragaz from the Univ. of British Columbia states that this information was utterly skipped and was not highlighted & neither bought to the notice of the oncologist community. He added that such information is nonetheless immensely significant since it added to the proof about estrogen’s breast cancer protection capability.

Part of WHI was stopped during 2002 that enrolled seventeen thousand females combination therapy takers. However a 2nd part enrolled ten thousand females that underwent hysterectomy procedure & were solely estrogen or dummy takers (progestin is used for counteracting detrimental impact of estrogen on the uterine region).

The solely-estrogen trial was halted sooner two years later, prior to estrogen’s impact could be totally assessed. However during supplementary examinations that appeared in the JAMA during 2004 and two years later & assessed once more during the San Antonio meet, scientists revealed statistical significant data indicative of the fact that estrogen intake considerably reduced breast cancer risk among certain females.

For example, in 8500 females having no kin history of breast cancer, using estrogen reduced risk for the disease by thirty-two percent in comparison to the same females who took placebo. From the 7600 females having no history of benignant breast conditions such as lump or cyst formations, women who took estrogen had a forty-three percent lesser risk of developing the disease.

It is not suggested that females must begin taking estrogen for breast cancer prevention, however the accumulating data would be assuring to females who have undergone hysterectomy procedure & are using estrogen for allaying menopausal symptoms. Around 1/3rd of the females in their post-menopause phase had opted for hysterectomy procedure.

Doctor Ragaz along with other specialists stated that most importantly, such assessments indicate a potential novel region of study for preventing breast cancer. But, the scientists regrettably confessed to funds for novel estrogen studies being exhumed even since the release of the WHI outcomes during 2002.

According to WHI researcher Doctor J. Manson from Brigham & Women’s Hosp. these results are interesting and are yet pilot, however the true inference will be in creating novel approaches for preventing breast cancer & to build on such discoveries to comprehend the reason for solo estrogen seeming to lessen breast cancer risk.

Some experts believe that the reason for estrogen takers being shielded from breast cancer could be since estrogen therapy obstructs the effects of a female’s innate estrogen, alike estrogen-obstructing tamoxifen medication.